Discovery may lead to targeted therapies to interrupt cancer development
(Philadelphia, PA) - Researchers at the Abramson Family Cancer Research Institute at the University of Pennsylvania have determined that a key enzyme, Pim-2, is responsible for the survival of cancer cells. The finding - which will appear in the August 1 edition of the journal Genes & Development - represents an important advance in understanding why cancer cells survive in the body (working against the body's natural immune system), before growing into tumors. It also answers a 20-year-old question as to the purpose of Pim-2, an enzyme present in high concentrations in many tumors, but left unstudied to this time; and it equates Pim-2 with another, more commonly studied survival pathway, the Akt-enzyme pathway.
"This finding is important because it shows, for the first time, how Pim-2 works and its key role in cancer cell survival," said Craig Thompson, MD, Principal Investigator of the study and Scientific Director of the Abramson Family Cancer Research Institute (AFCRI). "Up until now, predominant thinking has looked to the Akt pathway as the primary pathway for cancer cells. Now we know that Pim-2 plays an equally important role - and it is as much of a cancer-promoting gene, or oncogene, as Akt.
"Our next step is to try and manipulate the action of Pim-2, so that we can interfere with the survival of cancer cells," said Thompson. "Ultimately, the hope is that this could lead to new, targeted therapies for killing cancer cells before they turn into deadly tumors that can spread elsewhere in the body."
Pim-2 was originally identified, in 1984, as a serine/threonine kinase, one of several hundred principal oncogenes under investigation for their role in cancer cell survival and growth. Its mutated form has been observed in high quantities in cases of prostate cancer, leukemia and multiple myeloma. Close to 50 kinases are thought to play a key role in cancer progression. Through a process of elimination, scientists test each oncogene for its role or function in cancer progression, manipulating each gene, to see which changes, called mutations, allow the cell to live, and which ones let the cell die.
In the presence of Pim-2, sixty per cent of cancer cells survived attempts to starve or kill the cell. Cancer cells survived for the maximum duration in the study - up to three weeks - with Pim-2 present, regardless of whether or not growth factor (food for the cell) was present. Only when both the Akt pathway and Pim-2 pathway were dysregulated (no longer functioning inside the cell), were cancerous cells unable to survive and died. The Akt pathway is well studied because it plays many roles in cancer progression, including a key role in cancer cell survival.
Both Pim-2 and Akt survival pathways were found to operate independently; Pim-2 was not activated by any of the Akt pathway regulating enzymes - PI3K, HSP-90 and TOR. While Akt interacts with other enzymes to promote cell survival, the function of Pim-2 is independent, with no other enzymes required. The pathways were shown to be distinct by their response to the antibiotic rapamycin: Akt is sensitive to rapamycin and Pim-2 is not. Rapamycin is a commonly used drug for treatment of transplant patients, it restrains the body's immune response from rejecting foreign growths, such as a new organ. Pim-2 overcomes this potent inhibitor of cell survival.
While these pathways appeared distinct, they are not completely different and both have some common actions. One factor shared by both pathways is a phosphorylated "off signal" suppressor protein called 4E-BP1. Suppressor genes prevent the cancer cell from growing, so when turned "off", the cell can grow.
Exposing the role of Pim-2 was accomplished through the latest technology for cancer research, a micro-array analysis of RNA in the immune systems of mice.
Penn scientists focused their research on the question of why cancer cells survive - and not simply removed from the body by the immune system. For tumor cells to grow, they must have the ability to ignore "death signals" that would cause them to die, and not promote cancer. Pim-2 had been shown as an important gene in causing tumors in mouse experiments, and was also present in large amounts in tumors. Over-production of Pim-2 allows the cells to ignore or become insensitive to boosters of the immune system, such as the antibiotic rapamycin. The study took two years to complete (mid-2000 to mid-2002). Funding was provided through grants from the National Cancer Institute and the AFCRI.
CONTACT: David March
You may also find this news release with photos available on-line at www.uphs.upenn.edu/news
PENN Medicine is a $2.2 billion enterprise dedicated to the related missions of medical education, biomedical research, and quality patient care. PENN Medicine consists of the University of Pennsylvania School of Medicine (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System (created in 1993 as the nation's first integrated academic health system).
Penn's School of Medicine is ranked #2 in the nation for receipt of NIH research funds; and ranked #4 in the nation in U.S. News & World Report's most recent ranking of top research-oriented medical schools. Supporting 1400 fulltime faculty and 700 students, Penn's School of Medicine is recognized worldwide for its superior education and training of the next generation of physician/scientists and leaders of academic medicine.
Penn's Health System consists of four hospitals (including its flagship Hospital of the University of Pennsylvania, consistently rated one of the nation's "Honor Roll" hospitals by U.S. News & World Report); a faculty practice plan, a primary-care provider network, three multispecialty satellite facilities, and home healthcare and hospice.
OncoLink is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through OncoLink should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem or have questions or concerns about the medication that you have been prescribed, you should consult your health care provider.
Information Provided By: www.oncolink.org | © 2016 Trustees of The University of Pennsylvania